Safety

Important Safety Information

For Pharma® (vutrisiran)

Boxed Warning

See full Prescribing Information for the most serious risks associated with this medication. Patients should discuss all benefits and risks with their healthcare provider before starting therapy.

IMPORTANT SAFETY INFORMATION INDICATION Pharmaeda® (vutrisiran) is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. CONTRAINDICATIONS None. WARNINGS AND PRECAUTIONS Reduced Serum Vitamin A Levels and Recommended Supplementation. Pharmaeda treatment leads to a decrease in serum vitamin A levels. Supplementation at the recommended daily allowance is advised. ADVERSE REACTIONS The most common adverse reactions (≥5% and at least 3% more frequent than placebo) were pain in extremity, arthralgia, dyspnea, and decreased vitamin A. Please see Full Prescribing Information. This material is intended for U.S. Healthcare Professionals and pharma client teams only. Confidential.